Issue 10, Volume 128

Cover Figure: Cooperative germ line JAK2 mutations leading to hereditary erythrocytosis. See the article by Kapralova et al.

WASHINGTON, September 8, 2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

The genetics of nodal marginal zone lymphoma
Spina and colleagues combine next-generation sequencing and single nucleotide polymorphism arrays to analyze the genetics of nodular marginal zone lymphoma (NMZL). They identify common and divergent patterns of gene expression that may help to distinguish NMZL from splenic marginal zone lymphoma, which otherwise are distinguishable only by patterns of histologic dissemination.

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Selective targeting of BCL-2 with venetoclax has shown remarkable efficacy in treating refractory chronic lymphocytic leukemia. Here, Khaw and colleagues examine the effectiveness of venetoclax in treating pediatric acute lymphoblastic leukemia (ALL) xenografts. They report that the drug is extremely effective in treating mixed-lineage leukemia (MLL)–rearranged ALL but that therapy of other ALL subtypes requires inhibition of both BCL-2 and BCL-XL.

Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy
Sun and colleagues performed a retrospective comparison of intravenous immunoglobulin vs corticosteroids for the treatment of immune thrombocytopenia (ITP) in pregnancy. Of 235 pregnancies associated with maternal ITP, only 98 required treatment; in these patients, there was no difference in platelet response or in neonatal outcomes between the two therapies.

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Elena and colleagues integrate molecular data into the chronic myelomonocytic leukemia (CMML)–specific scoring system (CPSS) and propose a new scoring system, CPSS–molecular prognostic model, to improve risk stratification. This system identifies 4 distinct CMML risk groups with markedly different prognosis with overall survival ranging from 18 to 144 months and risk of AML progression from 0 to 48%.

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
Leblond and colleagues present new recommendations for the treatment of Waldenström macroglobulinemia. They highlight the role of established therapies using rituximab, cyclophosphamide, bendamustine, and bortezomib-containing combinations, and they discuss novel treatments with BTK inhibitors, B-cell receptor inhibitors, and new proteasome and mTOR inhibitors.

IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation
Sarvaria and colleagues report that cord blood is enriched with regulatory B cells (Bregs) that suppress allogeneic T-cell responses after cord blood transplantation. This opens the way for potential novel therapies targeting the Breg subset for the suppression of chronic graft-versus-host disease (cGVHD).

This week's complete table of contents

Why Submit to Blood?

Join the "This Week in Blood" mailing list by filling out the form below and clicking Subscribe!
*Email Address:
*First Name:
*Last Name:


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.